BACKGROUND: Awareness of chronic kidney disease (CKD) is low. Efforts are underway to increase recognition of CKD among patients, assuming that such an increase will lead to better outcomes through greater adherence to proven therapies. Few studies have tested this assumption. METHODS: CKD awareness, defined by a 'yes' answer to 'Have you ever been told by a healthcare provider you have weak or failing kidneys?', was assessed among 2,404 adults with CKD stages 1-4, who participated in the 2003-2008 National Health and Nutrition Examination Surveys. Odds of blood pressure (BP) control, self-reported use of angiotensin-converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB), and glycemic control, were determined among those aware vs. unaware of their CKD. RESULTS: Optimal BP control, ACEI/ARB use and glycemic control were low in the US adult population with CKD, although there was a recent increase in attainment of guideline-concordant BP control. Odds of BP control and ACEI/ARB use were not different among individuals aware of their CKD compared to those unaware (adjusted odds ratio (AOR) 0.91; 95% CI 0.52-1.58 and AOR 0.75; 0.44-1.30, respectively). CKD awareness among diabetic participants was not associated with glycemic control (AOR 0.41; 95% CI 0.14-1.18). CONCLUSION: Awareness of CKD is not associated with more optimal BP control, ACEI/ARB use or glycemic control. Future efforts in this area should further explore the measurement of CKD awareness and behaviors associated with CKD awareness.
BACKGROUND: Awareness of chronic kidney disease (CKD) is low. Efforts are underway to increase recognition of CKD among patients, assuming that such an increase will lead to better outcomes through greater adherence to proven therapies. Few studies have tested this assumption. METHODS: CKD awareness, defined by a 'yes' answer to 'Have you ever been told by a healthcare provider you have weak or failing kidneys?', was assessed among 2,404 adults with CKD stages 1-4, who participated in the 2003-2008 National Health and Nutrition Examination Surveys. Odds of blood pressure (BP) control, self-reported use of angiotensin-converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB), and glycemic control, were determined among those aware vs. unaware of their CKD. RESULTS: Optimal BP control, ACEI/ARB use and glycemic control were low in the US adult population with CKD, although there was a recent increase in attainment of guideline-concordant BP control. Odds of BP control and ACEI/ARB use were not different among individuals aware of their CKD compared to those unaware (adjusted odds ratio (AOR) 0.91; 95% CI 0.52-1.58 and AOR 0.75; 0.44-1.30, respectively). CKD awareness among diabeticparticipants was not associated with glycemic control (AOR 0.41; 95% CI 0.14-1.18). CONCLUSION: Awareness of CKD is not associated with more optimal BP control, ACEI/ARB use or glycemic control. Future efforts in this area should further explore the measurement of CKD awareness and behaviors associated with CKD awareness.
Authors: Julie A Wright; Kenneth A Wallston; Tom A Elasy; T Alp Ikizler; Kerri L Cavanaugh Journal: Am J Kidney Dis Date: 2010-12-18 Impact factor: 8.860
Authors: Carmen A Peralta; Leroi S Hicks; Glenn M Chertow; John Z Ayanian; Eric Vittinghoff; Feng Lin; Michael G Shlipak Journal: Hypertension Date: 2005-04-25 Impact factor: 10.190
Authors: Gerald M Devins; David C Mendelssohn; Paul E Barré; Kenneth Taub; Yitzchak M Binik Journal: Am J Kidney Dis Date: 2005-12 Impact factor: 8.860
Authors: Sri Lekha Tummalapalli; Eric Vittinghoff; Deidra C Crews; Mary Cushman; Orlando M Gutiérrez; Suzanne E Judd; Holly J Kramer; Carmen A Peralta; Delphine S Tuot; Michael G Shlipak; Michelle M Estrella Journal: Am J Nephrol Date: 2020-04-29 Impact factor: 3.754
Authors: Carmen A Peralta; Jennifer Livaudais-Toman; Marilyn Stebbins; Lowell Lo; Andrew Robinson; Sarita Pathak; Rebecca Scherzer; Leah S Karliner Journal: Am J Kidney Dis Date: 2020-07-22 Impact factor: 8.860
Authors: Sai H Dharmarajan; Jennifer L Bragg-Gresham; Hal Morgenstern; Brenda W Gillespie; Yi Li; Neil R Powe; Delphine S Tuot; Tanushree Banerjee; Nilka Ríos Burrows; Deborah B Rolka; Sharon H Saydah; Rajiv Saran Journal: Am J Prev Med Date: 2017-04-11 Impact factor: 5.043
Authors: Delphine S Tuot; Yunnuo Zhu; Alexandra Velasquez; Juan Espinoza; C Damaris Mendez; Tanushree Banerjee; Chi-Yuan Hsu; Neil R Powe Journal: Clin J Am Soc Nephrol Date: 2016-06-23 Impact factor: 8.237
Authors: Delphine S Tuot; Laura C Plantinga; Suzanne E Judd; Paul Muntner; Chi-Yuan Hsu; David G Warnock; Orlando M Gutiérrez; Monika Safford; Neil R Powe; William M McClellan Journal: Am J Nephrol Date: 2013-01-31 Impact factor: 3.754
Authors: Shaheen Kurani; Molly Moore Jeffery; Bjorg Thorsteinsdottir; LaTonya J Hickson; Erin F Barreto; Jordan Haag; Rachel Giblon; Nilay D Shah; Rozalina G McCoy Journal: J Gen Intern Med Date: 2019-12-02 Impact factor: 5.128
Authors: Delphine S Tuot; Charles E McCulloch; Alexandra Velasquez; Dean Schillinger; Chi-Yuan Hsu; Margaret Handley; Neil R Powe Journal: Am J Kidney Dis Date: 2018-04-23 Impact factor: 8.860
Authors: Cara B Litvin; Paul J Nietert; Ruth G Jenkins; Andrea M Wessell; Lynne S Nemeth; Steven M Ornstein Journal: J Gen Intern Med Date: 2019-12-10 Impact factor: 5.128
Authors: Chi D Chu; Charles E McCulloch; Tanushree Banerjee; Meda E Pavkov; Nilka R Burrows; Brenda W Gillespie; Rajiv Saran; Michael G Shlipak; Neil R Powe; Delphine S Tuot Journal: Am J Kidney Dis Date: 2020-04-15 Impact factor: 8.860